| Literature DB >> 35888080 |
Farheen Badrealam Khan1, Mohammad Azam Ansari2, Shahab Uddin3,4,5, Abdul Rasheed Palakott1, Irfa Anwar1, Ahmad Almatroudi6, Mohammad N Alomary7, Faris Alrumaihi6, Faris F Aba Alkhayl6,8, Saad Alghamdi9, Khalid Muhammad1, Chih-Yang Huang10,11,12,13,14, Jayasimha Rayalu Daddam15, Haroon Khan16, Sajid Maqsood17,18, Mohammed Akli Ayoub1,18.
Abstract
Camel milk (CM) constitutes an important dietary source in the hot and arid regions of the world. CM is a colloidal mixture of nutritional components (proteins, carbohydrates, lipids, vitamins, and minerals) and non-nutritional components (hormones, growth factors, cytokines, immunoglobulins, and exosomes). Although the majority of previous research has been focused on the nutritional components of CM; there has been immense interest in the non-nutritional components in the recent past. Reckoning with these, in this review, we have provided a glimpse of the recent trends in CM research endeavors and attempted to provide our perspective on the therapeutic efficacy of the nutritional and non-nutritional components of CM. Interestingly, with concerted efforts from the research fraternities, convincing evidence for the better understanding of the claimed traditional health benefits of CM can be foreseen with great enthusiasm and is indeed eagerly anticipated.Entities:
Keywords: bioactive peptides; camel milk; cancer; diabetes; exosomes; human diseases; molecular signaling; therapeutics
Year: 2022 PMID: 35888080 PMCID: PMC9318805 DOI: 10.3390/life12070990
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Figure 1Representative image delineating various active research endeavors related to CM in food sciences (A). Representative image delineating the beneficial effects of CM and its constituents against various human diseases (B).
Representative table delineating the therapeutic potential of Camel Milk and its constituents.
| S.No | Camel Milk Constituents | Cell Line/Animal Model/Assay Used | Mechanism | Reference |
|---|---|---|---|---|
| Cancer | ||||
|
| ||||
| 1 | Camel Milk | Human Hepatoma Cell Line (Hep-G2) and Human Breast Cancer Cell Line (MCF-7) | Induction of Apoptosis | [ |
| 2 | Camel Milk | Murine Hepatoma Hepa 1c1c7 Cell Line | Modulation of the expression of cancer-related genes (Cyp1a1), (Nqo1), and (Gsta1) at the transcriptional and post-transcriptional levels | [ |
| 3 | Camel Milk | Human Colorectal Cancer Cell line (HCT-116) and Breast Cancer Cell Line (MCF-7) | Induction of Autophagic Cell Death | [ |
| 4 | Lyophilised Camel Milk | Human Breast Cancer Cell Line (BT-474) | Induction of Apoptosis | [ |
| 5 | Camel Milk Lactoferrin | Human Colon Cancer Cell Line (HCT-116) | Inhibition of Human colorectal cancer cell line (HCT-116) proliferation and DNA damage inhibitory activities | [ |
| 6 | Camel Milk fermented with Camel Milk probiotic strain Lactococcus lactis KX881782 (Lc.K782) and control Lactobacillus acidophilus DSM9126 (La.DSM) | Human Colorectal Adenocarcinoma Cell Line | Inhibition of proliferation | [ |
| 7 | Camel Milk fermented with Camel Milk probiotic strains Lb. reuteri-KX881777, Lb. plantarum-KX881772, Lb. plantarum-KX881779 and a control strain Lb. plantarum DSM2468 | Human Colorectal Adenocarcinoma Cell Line | Inhibition of proliferation | [ |
| 8 | Camel Milk, Casein and Whey Proteins | Human Breast Cancer Cell Line (MCF-7) | Inhibition of proliferation as evident through MTT assay | [ |
| 9 | Camel Milk and Whey proteins | Human Adenocarcinoma Cell Line (HELA) | Inhibition of proliferation as evident through MTT assay | [ |
| 10 | TR35-An active fraction from Xinjiang Bactrian Camel Whey | In vitro Human Esophageal Carcinoma Cell Line (Eca-109) | Inhibition of Eca-109 cell proliferation and induction of apoptosis | [ |
| 11 | Camel Milk | Induced diethylnitrosamine and phenobarbitone Hepatic Cancer Wistar Rat Model | Potent Inhibitory effect on hepatocarcinogenesis in Wistar Rats was observed | [ |
| 12 | Camel Milk Whey Protein | Induced Azoxymethane (AOM)/Dextran sodium sulfate (DSS) Mouse Model | Inhibition of inflammatory colorectal cancer development via | [ |
| 13 | Camel Milk | Sponge implant angiogenesis Male Swiss Albino Mice Model | Inhibition of inflammatory angiogenesis via down-regulation of pro-angiogenic and pro-inflammatory cytokines | [ |
|
| ||||
| 14 | Camel Milk Exosomes | Human Colorectal Cancer Cell Line(HCT-116) and Human Breast Cancer Cell Line (MCF-7) | Induction of Autophagy | [ |
| 15 | Camel Milk Exosomes | Albino Rat Model | Mitigation of oxidative stress and immune-toxic responses induced by the chemotherapeutic drug viz. cyclophosphamide (CTX) | [ |
| 16 | Camel Milk Exosomes | HepaRG cells | Potential apoptotic, anti-inflammatory, and anti-angiogenesis effects against HepaRG cells | [ |
|
| ||||
| 1 | Camel Milk Protein and Lipid fractions | Colorimetry based analytical technique | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
| 2 | Bioactive Peptides from Camel Milk Protein Hydrolysates | Colorimetry based analytical technique | Inhibition of Angiotensin-1 converting enzyme (ACE) and anti-inflammatory responses | [ |
| 3 | Bioactive Peptides from Camel Milk Casein Hydrolysates | Colorimetry based analytical technique | Inhibition of Angiotensin-1 converting enzyme (ACE) and radical scavenging activities | [ |
| 4 | Camel Milk fermented with Camel Milk probiotic strain Lactococcus lactis KX881782 (Lc.K782) and control Lactobacillus acidophilus DSM9126 (La.DSM) | Colorimetry based analytical technique | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
| 5 | Camel Milk fermented with Camel Milk probiotic strains Lb. reuteri-KX881777, Lb. plantarum-KX881772, Lb. plantarum-KX881779 and a control strain Lb. plantarum DSM2468 | Colorimetry based analytical technique | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
| 6 | Fermented Skim Camel Milk | Spontaneously Hypertensive Rats | Attenuation of systolic and diastolic blood pressure, Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
|
| ||||
| 1 | Camel Milk and Protein Fractions | Human Embryonic Kidney Cell Line (HEK-293) | Allosteric effect on insulin receptor conformation and activation; and modulation of downstream signalling | [ |
| 2 | Camel Milk Whey Protein and Camel Milk Whey Protein Hydrolysates | Human Liver Cancer Cell Line (Hep-G2) and Human Embryonic Kidney Cell Line (HEK-293) | Inhibition of Dipeptidyl peptidase-IV (DPP-IV), Activation of insulin receptor and Positive Regulation on Glucose Uptake | [ |
| 3 | Camel Milk Protein Hydrolysates | Colorimetry based analytical technique | Inhibition of α-amylase | [ |
| 4 | Camel Milk Whey Protein Hydrolysates | Colorimetry based analytical technique | Inhibition of α-amylase and α-glucosidase | [ |
| 5 | Camel Whey Protein Hydrolysates | Colorimetry based analytical technique | Inhibition of Dipeptidyl peptidase-IV (DPP-IV) and inflammation | [ |
| 6 | Camel Milk Protein Hydrolysates | Colorimetry based analytical technique | Inhibition of Dipeptidyl peptidase-IV (DPP-IV) | [ |
| 7 | Camel Milk Protein Hydrolysates | Colorimetry based analytical technique | Inhibition of Dipeptidyl peptidase-IV (DPP-IV) | [ |
| 8 | Camel Whey Protein Enriched Hydrolysates | Colorimetry based analytical technique | Inhibition of Dipeptidyl peptidase-IV (DPP-IV) | [ |
| 9 | Camel Milk Protein Hydrolysates | Streptozotocin (STZ)-induced Diabetic Rats | Potent Hypoglycemic activity, as evident by reduction in fasting Blood Glucose and Oral glucose tolerance test (OGTT) levels; Preservation of β-cells was also observed | [ |
| 10 | Camel Milk Protein Lactoferrin | HEK-293 and Hep-G2 cells | Modulation of Insulin Receptor and downstream signalling | [ |
|
| ||||
| 1 | Camel Milk Casein Protein hydrolysates and its fraction | Significant anti-microbial activity was observed against all the microbial strain tested for all the fractions | [ | |
| 2 | Camel Whey Proteins and hydrolysates |
| Improved anti-microbial activities of Camel Whey Proteins were observed, particularly for limited Proteolysed fractions | [ |
| 3 | Lysozyme(LZ), lactoferrin(LF), lactoperoxidase(LP), immunoglobulin G (IgG) and secretory immunoglobulin A(Ig A) extracted from camel milk |
| Camel milk LF showed intriguing antibacterial activity. The camel milk LP was bacteriostatic against the Gram-positive strains and was bactericidal against Gram-negative cultures. The immunoglobulins had little effect against the bacteria but high titres of antibodies against rotavirus were found in camel milk. The LP system was ineffective against rotavirus | [ |
| 4 | Camel Casein Proteins and hydrolysates |
| Camel milk casein hydrolysates exhibited anti-bacterial activity; Gram-positive strain growth was not affected by intact camel casein fraction, whereas the respective hydrolysates slightly inhibited the growth of the bacteria | [ |
| 5 | Camel and Cow Casein Proteins and hydrolysates |
| Camel milk protein hydrolysates were more potent in inhibiting pathogenic Candida species compared with cow milk protein hydrolysates | [ |
Representative table highlighting some of the putative bioactive peptides from Camel Milk.
| S.No | Bioactive Peptide | Mechanism | Reference |
|---|---|---|---|
| Hypertension | |||
| 1 | AIPPKKNQD | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
| 2 | DLENLHLPLPL; LTDLENLHLPLPL;TDLENLHLPLP; TDLENLHLPLPL; | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
| 3 | LSLSQFKVLPVPQ; KVLPVPQQMVPYPQ;TDLENLHLPLPL | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
| 4 | AEWLHDWKL; SHSPLAGFR; LTMPQWW; CLSPLQMR and CLSPLQFR | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
| 5 | QSAPGNEAIPP | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
| 6 | MVPYPQR | Inhibition of Angiotensin-1 converting enzyme (ACE) | [ |
|
| |||
| 1 | FLQY; FQLGASPY; ILDKEGIDY; ILELA; LLQLEAIR; LPVP; LQALHQGQIV; MPVQA; and SPVVPF | Inhibition of Dipeptidyl peptidase-IV (DPP-IV) | [ |
| 2 | VPV, YPI and VPF | Inhibition of Dipeptidyl peptidase-IV (DPP-IV) | [ |
| 3 | DNLMPQFM and WNWGWLLWQL | Inhibition of Dipeptidyl peptidase-IV (DPP-IV) | [ |
| 4 | INNQFLPYPYWL and IPAVF | Inhibition of Dipeptidyl peptidase-IV (DPP-IV) | [ |
Figure 2Representative image delineating the anti-cancer effect of CM against human colorectal and breast cancer cells through induction of autophagic responses (abbreviations are: LC3: a microtubule- associated protein 1 light chain 3 (LC3-I precursor); PE: phosphatidylethanolamine; LC3-II: Lipidated LC3-I; ATG4 and ATG7, autophagy proteins; ATG5-12, a complex of autophagy proteins; p62: sequestosome 1). Modified from Izadi et al., Journal of Functional food [24].
Figure 3Representative image delineating the plausible anti-hypertensive effect of CM. At the molecular level, the renin-angiotensin system (RAS) is at the center of the regulation of hypertension. Angiotensin II (Ang II), an important effector RAS hormone, has been implicated in regulating the physiological effects of the regulation of blood pressure and is associated with the pathophysiology of hypertension. Basically, Ang II is derived from Ang I through the activity of Angiotensin Converting Enzyme (ACE). ACE, or kininase II, also plays a key role in the kallikrein-kinin system by cleaving bradykinin to inactive peptides; which, in turn, also affect hypertensive responses (A). Molecular signaling through AT1R is envisaged to mediate aldosterone secretion, ADH secretion, and the arterial vasoconstriction, which ultimately leads to hypertensive response (B). A detailed overview of the molecular signaling mediated by Ang II-AT1R is delineated (C). Interestingly, CM and its constituents have been reported to inhibit ACE.
Figure 4Representative image delineating the plausible anti-diabetic effect of CM. Food breakdown in the gastrointestinal tract (GI) leads to release of gut hormones, such as Glucagon-Like Peptide-1 (GLP-1) and Glucose Dependent Insulinotropic Polypeptide (GIP), which seemingly stimulate glucose-dependent insulin secretion by the pancreatic Beta cells. Insulin thereby promotes glucose uptake by the insulin sensitive tissues. Mechanistically, insulin, upon binding to insulin receptors, initiates a signaling cascade that eventually induces translocation of glucose receptors (GLUTs) to the membrane whereby glucose can be up-taken. These gut hormones are cleaved by DPP-IV enzymes which leads to attenuation of insulin secretion. Interestingly, CM and its constituents have been reported to activate GLP1/GIP and inhibit Dipeptidyl peptidase-IV (DPP-IV), activate insulin receptor and inhibit glucagon receptor. Additionally, it has been reported that CM embodies insulin-like peptides that mimic insulin responses, another aspect adding to their anti-diabetic potential.